De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms. We investigated the effects of radiprodil, a selective GluN2B negative allosteric modulator and other nonselective NMDA receptor inhibitors on glutamate currents mediated by NMDA receptors containing mutated GluN2B subunits. The experiments were performed in Xenopus oocytes co-injected with the following human mRNAs: GRIN1/GRIN2B, GRIN1/GRIN2B-R540H, GRIN1/GRIN2B-N615I and GRIN1/ GRIN2B-V618G. Glutamate displayed slightly increased potency in the R540H variant, but not in N615I and V618G variants. However, the inhibition by Mg 2þ was completely abolished in N615I and V618G
Introduction
An imbalance between inhibitory and excitatory neurotransmission leads to hyperexcitability and seizures, a hallmark of epilepsy. Glutamate is a key excitatory neurotransmitter and compounds inhibiting the ionotropic N-methyl-D-aspartate receptor (NMDA) have anticonvulsant activity in rodents (Naylor et al., 2013; Zaitsev et al., 2015) and in humans (Shields, 2006; Zupanc et al., 2010) . However, side-effects have limited the therapeutic use of non-selective NMDA receptor inhibitors and molecules that target specific subunits of the NMDA receptor have been developed, with the hope of better clinical tolerability (Kornhuber and Weller, 1997; Low and Roland, 2004) .
NMDA receptors form heterotetrameric assemblies that are usually composed of two copies of GluN1 and GluN2(A-D) subunits, which bind glycine and glutamate respectively (Flores-Soto et al., 2012) . These subunits not only have similar sequences but adopt similar modular domain architectures as observed in the recently solved full-length X-ray crystal structures and electron cryomicroscopy structures (Karakas and Furukawa, 2014; Lee et al., 2014; Tajima et al., 2016; Zhu et al., 2016) . Amino-terminal domains (ATDs) and ligand-binding domains (LBDs) are located on the extracellular aspect of the membrane, while a transmembrane domain (TMD) spans the membrane, and the intracellular carboxyterminal domain resides within the cytoplasm. Under physiological conditions, these receptors are activated by concurrent binding of glycine and glutamate, and concomitant depolarization of the membrane potential to relieve voltage-dependent Mg 2þ block (Mayer et al., 1984; Nowak et al., 1984) . Single-channel properties are influenced by the exact subunit composition, which confers specific functions in the brain (Glasgow et al., 2015) . There is ample evidence that NMDA receptors containing GluN2B subunits are involved in pathogenic mechanisms. Predominantly enriched at extrasynaptic sites, GluN2B containing receptors contribute to sustained tonic currents, activation of pro-apoptotic genes and to neuronal death (Liu et al., 2007; Groc et al., 2009; Sanz-Clemente et al., 2013) . In chronically epileptic animals, GluN2B subunits are upregulated and may contribute to seizure susceptibility and epileptogenesis (Yang et al., 2006; Ghasemi and Schachter, 2011) . By contrast, blockade of GluN2B receptors is neuroprotective (Wang and Bausch, 2004; Yuan et al., 2015) and have anticonvulsant effects in rodent seizure models (Williams, 2001; Mares and Mikulecka, 2009) . Mutations in the GRIN2B gene encoding GluN2B subunits have been identified in idiopathic focal epilepsy (Endele et al., 2010; Lemke et al., 2014) . Recently, de novo GRIN2B missense mutations were reported in 2 patients with epileptic encephalopathy and one patient with intellectual disabilities and childhood onset epilepsy, suggesting that GRIN2B variants might be a risk factor for several epileptic disorders (Lemke et al., 2014) . Electrophysiological studies revealed a gain of function phenotype that may be the underlying cause of epilepsy in the subjects carrying these GRIN2B mutations (p.Arg540His, p.Asn615Ile and p.Val618Gly). Mutations in GRIN2A encoding GluN2A subunits have also been described in idiopathic focal epilepsy with rolandic spikes, epileptic encephalopathy and epilepsy-aphasia syndrome (DeVries and Patel, 2013; Lemke et al., 2013; von Stulpnagel et al., 2017) . Interestingly, depending on the location of the mutation, some variants display a loss of function, while others display a gain of function, suggesting different pathogenic mechanisms might be involved in the epileptic phenotype (Endele et al., 2010; Addis et al., 2017) . This also highlights the importance of characterizing the functional consequences of each variant to develop adequate and personalized therapy for patients carrying mutations in different NMDA receptor subunits.
NMDA receptors can be regulated by a wide spectrum of modulators, from the non-selective small molecules (e.g. MK-801 and memantine), which bind within the central vestibule of the TMDs, to selective GluN2B negative allosteric modulators (e.g. ifenprodil and Ro 25-6981) that bind to the ATD (Monaghan et al., 2012; Karakas and Furukawa, 2014) . Radiprodil, part of the "prodil" chemical group, belongs to a second generation of molecules that have a nanomolar potency at GluN2B receptors (in cell assay measuring Ca 2þ influx), and enhanced oral bioavailability (Borza and Domany, 2006) . It is a negative allosteric modulator (NAM) of GluN2B-containing NMDA receptors and binds within the ifenprodil pocket of GluN2B displaying improved selectivity versus adrenergic and sigma receptors (Borza and Domany, 2006; Mony et al., 2009) . Radiprodil reached Phase 2 clinical development for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (Farkas et al., 2003; Gilron and Coderre, 2007) . The compound was well-tolerated, but stopped due to a lack of significant reduction in daily pain scores (RG8-MD-02; NCT00838799). The present study was designed to investigate whether radiprodil could inhibit glutamate currents mediated by NMDA receptors composed of GRIN2B variants previously linked with epileptic encephalopathies, which could support novel potential therapeutic applications in the future. We also compared radiprodil's effect with those of non-specific NMDA receptor inhibitors. Collectively, we aimed to provide pharmacological evidence for potential precision medicine based therapy of epileptic encephalopathies as recently demonstrated for other non-selective NMDA receptor inhibitors (Pierson et al., 2014; Marwick et al., 2015; Li et al., 2016) .
Materials and methods

Reagents
Radiprodil (2-[4-(4-Fluoro-benzyl)-piperidin-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-acetamide) was synthesized at UCB. Glutamate (L-Glutamic acid) from Sigma (Saint-Louis, MO) and glycine from BioRad (Hercules, CA) were diluted to their final concentration directly in the buffer solution used for the recordings. Test compounds radiprodil, memantine (Sigma) and MK-801 (Sigma) were dissolved in 100% DMSO as stock solution and frozen at À20 C and later diluted to appropriate concentrations (final concentration 0.1% DMSO).
Expression of human NMDA receptors in Xenopus oocytes
2.2.1. GRIN1 and GRIN2B constructs GRIN1 coding for GluN1-4a and GRIN2B (accession number NM_000834.3 for GRIN2B_Hs V3) constructs were generated by Genscript (Piscataway, NJ) using restriction sites NotI and XhoI. Mutations were introduced into these constructs. The following constructs were cloned into pcDNA3.
mRNA preparation
RNA preparations for oocyte injections were performed by RDBiotech (Besançon, France). All constructs were confirmed by digestion for correct insertion of the subunits in destination vectors. Linearization of the GRIN2B plasmids was performed with the restriction enzyme Xho I while linearization of the GRIN1 plasmid was performed with the restriction enzyme BamHI. Linearized plasmid was used for in vitro transcription using mScript standard mRNA production system (Cellscript, Madison, WI). After reaction, transcripts were capped, polyA tailed with components of this kit and purified. The size of the mRNA was confirmed by gel electrophoresis after purification and denaturation.
GluN1/GluN2B receptor expression in Xenopus oocytes
GRIN1/GRIN2B human mRNA was injected with an automated micro-injector (Roboocyte ® , Multi Channel Systems, Reutlingen, Germany) using a glass micropipette (5.5 mm diameter, MCS) into the cytoplasm of Xenopus oocytes (stage VeVI) previously dissected and de-folliculated (EcoCyte Bioscience, Castrop-Rauxel, Germany). Oocytes were microinjected with~25 nl of mRNA dissolved in RNAse free water (Ambion, Thermo Fisher Scientific, Waltham, MA). Receptors were allowed to express for 3e6 days at 17 C in a Barth's solution containing (in mM): NaCl (88), KCl (1), NaHCO 3 (2.4), Ca(NO 3 )2 (0.33), CaCl 2 (0.41), MgSO 4 (0.82), Tris-HCl (5) pH 7.4 and supplemented with penicillin/streptomycin (100 IU/ mL). Oocytes were washed every day with Barth's solution containing antibiotics.
For expression of GluN1/GluN2B receptors, the solution contained the transcripts coding for the different subunits at a concentration of 0.01 ng/nl. For the dose-response for glutamate experiments, all oocytes were injected with the same quantity of GRIN1/GRIN2B mRNAs (ratio 1:5, 0.25 ng total). However, GluN1/ GluN2B (N615I) and GluN1/GluN2B (V618G) variants displayed currents that were smaller than those elicited in GluN1/GluN2B (WT) and in GluN1/GluN2B R540H. Therefore, for subsequent experiments, the mRNA quantity was adjusted (2.5 ng total; 0.1 ng/nl solution, total volume ± 25 nl) for GluN1/GluN2B (N615I) and GluN1/GluN2B (V618G) variants in order to obtain suitable currents. currents were induced by co-application of 10 mM glutamate (Glu) and 1 mM glycine (Gly) in GluN1/GluN2B -expressing oocytes in all groups and all experiments. After 1 min of Glu/Gly application, one dose of the test compound was applied for 2 min and the percentage of inhibition was calculated. For compound concentrationresponse curves, only one concentration of compound was tested per oocyte. Data were pooled from different oocytes, with a total of three or more oocytes for each concentration, except at max concentrations, for which occasionally, only 2 oocytes were tested (indicated in text). A pH of 7.2 was used in all experiments, except for the studies on the effect of pH whereupon the pH values were varied. All experiments except the I-V curves were performed at À60 mV. Current-voltage (I-V) curves of Ca 2þ currents for glu (100 mM)/gly (10 mM)-activated currents were performed in NaCl 2 -free solution containing (in mM): NMDG (115), HCl (115), HEPES (10 mM) and CaCl 2 (1.8). For I-V curves, one set of oocytes was tested in the absence of Mg 2þ at all potentials (À90 to þ30 mV in 20 mV steps) and another set of oocytes was tested in the presence of Mg 2þ .
Two electrode voltage-clamp recordings (TEVC)
Data analysis
Currents were analyzed off line using the Roboocyte Software version 2. Glu/gly current inhibition by the drug was calculated based on the ratio I(Glu þ drug)/I(Glu). To control for potential sources of variation, current amplitudes in the presence of the compound were normalized to the maximal response of glu/Gly current values without the compound. Dose response curves were obtained by plotting average relative current amplitude (I/I0) as function of compound concentration. Concentrations were log transformed before analysis to generate a data set amenable to non-linear regression and to parametric statistical analysis. Dose response curves were analyzed by GraphPad software version 6.05 for Windows (San Diego CA) and pIC 50 values were calculated by non-linear regression analysis using a sigmoidal dose response equation equivalent to log(dose) vs. response (variable slope) Sigmoidal, 4PL, [Y¼Bottomþ(Top-Bottom)/1 þ 10^((LogEC 50 -X) *Hillslope)], X ¼ log of dose; Y ¼ response. To fit glutamate doseresponse curves, the top was fixed at 100. No weighting of the points was applied. In current-voltage curves, values were compared at each voltage in the absence and the presence of Mg 2þ by running a two-way ANOVA.
Statistical analyses were performed in GraphPad Prism. To determine statistical significant differences in non-linear regressions, GraphPad Prism was used to compare fits, using the extra sum-of-squares F test. For each dataset, the best-fit value of a parameter (LogIC 50 or IC 50 ) was compared from a hypothetical value (WT). Group means for all measures were compared using Student's t-tests for two group comparisons or ANOVA and Dunnett's multiple comparison tests to compare more than two groups. Differences were considered to be statistically significant when P < 0.05. Values are presented as mean ± SEM; n, number of oocytes or number of dose-responses as indicated in text. Statistical results in the figure legends represent the results of post hoc multiple comparisons (indicated by symbols in the figures).
Modelling
The missing sidechains and loops of the rat GluN1-GluN2B NMDA receptor structure 4PE5 were modeled back in using Completionist (http://opig.stats.ox.ac.uk/webapps/), with the engineered cross-links removed during this preparation step. A human model was then generated using Prime (Schr€ odinger, 2016) , and the sequence numbering of the Uniprot accession entries GluN1 (Q05586) and GluN2B (Q13224) were adopted in the resulting model as shown in Fig. 1 .
Results
Responses to glutamate and proton inhibition
Under physiological conditions, glutamate responses decrease greatly at acidic pH, due to the presence of external protons that inhibit channel conductance (Banke et al., 2005) . Hence, we investigated the effects of pH on the glutamate potency to activate GluN1/GluN2B receptors, and glutamate EC 50 values were measured at different pH values to determine if GRIN2B mutations modulated glutamate potency. At pH 7.6, and pH 7.0, EC 50 values did not vary between WT and variants N615I and V618G, suggesting that those two mutations do not interfere with glutamate potency (Fig. 2A) . However, glutamate EC 50 values in R540H were slightly, but statistically lower than in the WT at pH 7.6 (0.8 compared to 2.0 mM; P ¼ 0.002; F(DFn, DFd) ¼ 10.27 (1,58)) and at pH 7.0 (0.6 compared to 1.0 mM; P < 0.001; F(DFn, DFd) ¼ 41.13 (1,43)).
When lowering the pH from 7.6 to 7.0, the WT, R540H and N615I GRIN2B variants showed a similar decrease in current amplitude (~30% remaining) (Fig. 2B ). In the V618G variant, the proportion of remaining current at pH 7.0 was lower than in the WT (19 ± 1% vs 31 ± 2% respectively; P < 0001; F(3,23) ¼ 72.99). These findings suggest that proton inhibition is retained in all variants. Acidosis is a key mechanism for self-termination of seizures, and prolonged seizures and ischemia lead to brain acidification (Siesjo et al., 1985; Xiong et al., 2000) . It was therefore important to investigate if radiprodil maintained its potency under acidic conditions. Fig. 2C shows that at pH 7.0, the IC 50 for radiprodil in the WT was 2.8 fold lower than its IC 50 at pH 7.6 in the WT (P < 0.0001; F (DFn, DFd) ¼ 33.60 (1,72)), indicating that radiprodil's potency to block current under acidic conditions is higher than at physiological conditions.
Mutations in the transmembrane domain drastically change the responses to Mg 2þ
Since mutations in NMDA receptor subunits can lead to a loss of Mg 2þ sensitivity, we evaluated the percent block by Mg 2þ in each variant, at a single holding potential (À60 mV) and pH 7.2. The R540H variant displayed a Mg 2þ block similar to that of the WT, while in the N615I and V618G variants, Mg 2þ failed to block glutamate evoked currents, and even contributed to an increase of the current P < 0.0001 F(3,16) ¼ 144.7 (Fig. 3A and B) . (Nowak et al., 1984) . To determine whether the lack of Mg 2þ block could be explained by a shift in the voltage-dependence, we studied I-V relationship of currents induced by 100 mM glutamate (in the presence of 10 mM glycine) in Mg 2þ -free or in 1 mM Mg 2þ (pH 7.2). In the WT and the R540H variant, NMDA currents were smaller in the presence of Mg 2þ at hyperpolarized potentials P < 0.05 F(6,60) ¼ 2.751 for WT, significant at À90 mV and at À70 mV; P ¼ 0.0049 (Fisher's LSD) in R540H at À90 mV (Fig. 4) . At more depolarized potentials, currents were similar in the absence or presence of Mg 2þ indicating a removal of Mg 2þ block. By contrast, in the N615I variant, currents were not different in the absence or the presence of Mg 2þ at any negative potential indicating those variants are insensitive to Mg 2þ block (Fig. 4) .
In the V618G variant, current was significantly higher in the presence of Mg 2þ than in the absence of Mg 2þ at þ30 mV (Fisher's LSD P ¼ 0.01).
Functional impact of GRIN2B mutations on GluN2B-selective inhibition
To investigate the functional effect of mutations on the potency of a GluN2B selective blocker, we determined radiprodil's IC 50 values in GRIN2B WT and GRIN2B variants (pH 7.2). Radiprodil's potency to block NMDA currents was similar in all variants in Mg 2þ free conditions (Fig. 5A ). In addition, in the presence of Mg 2þ , radiprodil could block NMDA currents in Mg 2þ insensitive variants, with potencies similar to those obtained without Mg 2þ (Fig. 5B and Table 1 ). These data suggest that the GRIN2B mutations described here do not impact on the binding or efficacy of GluN2B selective inhibitors.
Effect of glycine concentrations on radiprodil block
Glycine is one of the endogenous co-agonists for NMDA receptors, and plays an important role in excitatory transmission, especially at extra-synaptic NMDA receptors, composed of GluN2B subunits that display up to tenfold higher affinity for glycine than GluN2A-containing NMDA receptors (Priestley et al., 1995; Papouin Fig. 1 . A. Architecture and domain organization of the heterotetrameric GluN1-GluN2B NMDA receptor (Protein data bank entry 5IOV following the preparation steps described in section 2.5). Adapted from (Zhu et al., 2016) . View of the receptor complex where the GluN1 and GluN2B subunits are shown in green and cyan respectively, with the co-crystallized GluN1-bound agonist glycine and GluN2B-bound agonist glutamate. The Ro 25-6981 NAM is shown in space-fill format bound to ATD. The Ca's of the GluN2B mutants that are the subject of this study, namely R540H, N615I and V618G, are depicted as silver, magenta and orange van der Waals spheres respectively. B. Close-up view of the GluN1 and GluN2B TMD architecture is shown. The GluN2B mutants N615I and V618G, displaying a loss of Mg 2þ block and abnormal block by non-specific NMDA receptor inhibitors, are depicted in magenta and orange van der Waals spheres respectively. The figures were generated using the Visual Molecular Dynamics software (Humphrey et al., 1996) . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 2 . Concentration-response curves for glutamate (in the presence of 1mM glycine) activation of GluN1/GluN2B, GluN1/GluN2B (R540H), GluN1/GluN2B (N615I) and GluN1/ GluN2B (V618G). Fitted EC 50 values for glutamate were similar in the two GRIN2B variants N615I and V618G compared to the WT variant at both pH 7.6 and pH 7.0. In the R540H variant, glutamate EC 50 was slightly lower compared to the WT (**: P < 0.01 at pH 7.6; yyy: P < 0.0001 at pH 7.0). Data represent mean ± SEM from 5 to 11 dose-response curves (n indicated in table). B. Traces show that glutamate responses (in the presence of 1mM glycine) decrease greatly when extracellular solution is switched from pH 7.6 to pH 7.0. Graph shows the ratio of currents at pH 7.0/currents at 7.6 that was normalized to the ratio of currents at pH 7.6/currents at pH 7.6 in each variant. The ratio of remaining current at acidic pH was similar in WT, R540H and N615I GRIN2B variants. It was slightly lower in the V618G variant (***P < 0.001). Data represent mean ± SEM from 5 to 8 oocytes. C. Concentrationresponse curves for radiprodil inhibition of GluN1/GluN2B (WT) at pH 7.0 and pH 7.6. At acidic pH 7.0, IC 50 for radiprodil was slightly lower than at pH 7.6 (see text for statistics). Data represent mean ± SEM from 4 to 6 oocytes. at À60 mV. B. Graph shows that Mg 2þ (1 mM) inhibited 80e95% of NMDA currents in GluN1/GluN2B (WT) and in the GluN1/GluN2B (R540H) variants. However, in GluN1/GluN2B (N615I) and GluN1/GluN2B (V618G) variants, Mg 2þ failed to inhibit and even increased NMDA-mediated currents. Data represent mean ± SEM from 2 to 7 oocytes. ***: P < 0.001 (ANOVA). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) et al., 2012). Elevated brain glycine levels have been identified in severe neonatal myoclonic encephalopathies (Dulac, 2013) . Therefore, we investigated whether glycine could modulate radiprodil's potency to block glutamate currents mediated by NMDA receptor activation. We found that radiprodil maintained its efficacy in high glycine concentrations in the WT and found no differences in IC 50
N615I and V618G vs WT, and vs R540H (see text for statistics
values for radiprodil at 1 mM glycine (0.12 mM; n ¼ 9), 10 mM glycine (0.15 mM; n ¼ 8), 100 mM glycine (0.17 mM; n ¼ 7) and 1000 mM glycine (0.11 mM; n ¼ 11) (P > 0.05, F (DFn, DFd) ¼ 1.837 (3268); data not shown).
Functional impact of GRIN2B mutations on non-specific NMDA receptor antagonists
MK-801 is a non-selective NMDA channel pore blocker, which is believed to bind within a central vestibule located in the TMD; in close proximity with some of the mutations studied, namely N615I and V618G (Bachurin et al., 2001; Lee et al., 2014) . MK-801 blocked glutamate currents with different potencies in WT and GRIN2B variants. In the R540H variant, the potency for MK-801 was similar to the WT while in the two N615I and V618G variants, it was nearly 30-fold lower than in the WT (Fig. 6, Table 1 ).
Memantine is another non-selective NMDA receptor channel pore blocker, that is also believed to bind in the central vestibule formed within the TMD. In the R540H variant, the potency for memantine was similar to the WT, while in the N615I variant the IC 50 value (300 nM) was slightly but significantly lower (P < 0.001) than in the WT (521 nM). By contrast, the IC 50 value in the V618G variant was greatly increased (17.4 mM) compared to the WT (P < 0.001). In Mg 2þ , the potency of memantine to block NMDA currents was also lower in the V618G variant (IC 50 ¼ 16.7 mM) compared to the N615I variant (IC 50 ¼ 241 nM; P < 0.001; Fig. 6 ; Table 1 ).
Discussion
Our results confirmed data previously reported by (Lemke et al., 2014) and (Swanger et al., 2016) showing alterations of NMDA receptor mediated currents indicative of gain of function in several GRIN2B variants associated with epileptic encephalopathies. Importantly, we provide both novel additional evidence describing the gain of function of these GRIN2B variants and comparative pharmacology data supporting potential therapeutic use of selective GluN2B NAM compounds to treat hyperexcitability and seizures observed in patients carrying these mutations.
Alteration of currents in GRIN2B variants indicative of gain of function
Responses to glutamate
The R540H mutant displayed a 3 fold increase in glutamate potency at pH 7.6, but at more acidic pH, the difference was less than two fold, which could explain why it was not significantly different in another report (Lemke et al., 2014) but is in line with a recently published study (Swanger et al., 2016) . The increased glutamate potency in the R540H variant could lead to larger current amplitudes at physiological glutamate concentrations and to increased vulnerability of cells to glutamate as described for other mutations (Li et al., 2016) . Looking at the recently solved intact structures of the NMDA receptor (Tajima et al., 2016; Zhu et al., 2016) , the R540H variant is located on the LBD in close proximity to LBD-TMD linker. We propose that the effect of this mutant could be explained by the fact that position R540 is implicated in communicating structural changes arising from agonist binding to the TMD and that the H540 may not be able to cascade this signal as efficaciously.
In a previous study, the mutant R540H also displayed prolonged Fig. 4 . The lack of Mg 2þ block is not due to a shift in voltage-dependence. Graphs show current-voltage curves in Mg 2þ -free and in 1 mM Mg 2þ for each variant. In WT-and R540H-injected oocytes, current amplitudes at À90 and À70 mV were smaller in the presence of Mg 2þ while in N615I and V618G variants, current amplitudes were similar in the absence or presence of Mg 2þ indicating that Mg 2þ block is absent in those variants. Data represent mean ± SEM from 3 to 7 input-output curves (on parentheses). *: P < 0.05 for WT in the absence of Mg 2þ , significantly different than WT in the presence of Mg 2þ at À90 mV and at À70 mV yy: P ¼ 0.0049 in R540H at À90 mV (Mg 2þ versus no Mg 2þ ).
deactivation rates, measured in HEK cells, more suited for the measurement of currents induced by fast application of glutamate (Swanger et al., 2016) . The authors proposed that altered kinetics could also affect synaptic transmission in deleterious variants.
Response to Mg 2þ
We demonstrated a clear gain of function in two GRIN2B variants variant in the presence of Mg 2þ . Voltage-dependent Mg 2þ block was absent in the N615I and V618G variants at À90 and À70 mV. These results confirm the previously reported loss of Mg 2þ inhibition in the same GRIN2B variants (Lemke et al., 2014) . In their study, Lemke et al. found a significant loss of Mg 2þ inhibition in the N615I and V618G variants and a small decrease in the R540H variant. We report that the most pronounced dysfunction in Mg 2þ block was also found in the N615I and V618G variants while there was no difference in the R540H variant. Furthermore, our data show that adding Mg 2þ after induction of glutamate currents increased current amplitude, an observation that has not been reported for these variants. This suggests that GluN1/GluN2B(N615I) and GluN1/GluN2B (V618G) receptors display permeability to Mg 2þ upon glutamate activation, or that Mg 2þ potentiates currents carried by Na þ . An increase in Mg 2þ permeability has been described after asparagine substitution in GluN2B subunits in the transmembrane segment M2, indicating that the increase observed here might also be due to permeation of Mg 2þ (Burnashev et al., 1992; Kashiwagi et al., 2002) . The TMD of the NMDA receptor consists of four a-helices, M1 to M4, with M1 to M3 forming the ion channel pore (Fig. 6 ). M1 and M3 are connected by an M2 pore helix, and a pore loop which forms the selectivity filter where residues N615 and V618 are located. The increase of Mg 2þ permeability after substitution of asparagine by isoleucine and of valine by glycine can be explained by a decreased ability to selectively coordinate the Mg 2þ cations in the selectivity filter of the ion channel pore (Dingledine et al., 1999) . The abnormal Mg 2þ effect we report in our study could also be explained by increased potentiation of glu/gly currents upon Mg 2þ binding. Indeed,
another study reported that Mg 2þ potentiation occurring in different variants was dependent on the ATD as removal of the GluN2B ATD eliminated Mg 2þ potentiation (Wilcox et al., 2016) .
Increased Mg 2þ permeability or Mg 2þ potentiation is likely to lead to a sustained depolarization followed by massive and sustained Ca 2þ entry, which would be damaging for neurons.
Furthermore, since brain extracellular Mg 2þ concentrations are high, neurons expressing those variants would depolarize, even at resting membrane potential. As such, selective GluN2B inhibitors may normalize NMDA-mediated currents and potentially exert therapeutic effects in subjects carrying these mutations.
Blockade of NMDA receptors encoded by GRIN1/GRIN2B variants 4.2.1. Blockade by radiprodil
The efficacy and potency of the GluN2B inhibitor radiprodil to block glutamate-induced currents was similar in WT and all three GRIN2B variants. For the Mg 2þ insensitive variants N615I and V618G, radiprodil was also able to block NMDA-induced currents with similar potencies in the presence and in the absence of Mg 2þ .
This suggests that in vivo, where extracellular Mg 2þ concentrations are high at physiological levels, radiprodil is likely to inhibit NMDA currents in the Mg 2þ insensitive variants. This also indicates that those mutations do not affect the radiprodil binding site, or its efficacy. The three GRIN2B mutations ( Fig. 1 ) located in the LBD (R540H) and the TMD (N615I, V618G) are distant from the radiprodil binding site e located extracellularly, in the ATD (Mony et al., 2009) . These observations together with the likelihood that the structural changes that are transmitted from the ATD to the LBD and eventually to the TMD are not deleteriously influenced by these mutants, explain why radiprodil's inhibitory effect is unchanged in the mutated receptors tested in the present study.
Non-specific NMDA receptor blockers
By contrast, non-specific NMDA receptor blockers displayed altered potency in the two variants for which amino acids were substituted in the TMD, GRIN2B(N615I) and GRIN2B(V618G) but not in the variant with a substituted arginine in the ATD GRIN2B(R540H). In the V618G variant, the potencies for memantine and MK-801 were decreased by 20 and 29 fold, respectively. In the N615I variant, only the potency for MK-801 was decreased by~29 fold while the potency for memantine was increased by two fold. Our results are in line with previous mutagenesis work, reporting alterations of NMDA receptor inhibitor IC 50 values based on single point mutations in the ion channel pore (Kashiwagi et al., 2002; Limapichat et al., 2013) . In a recently published structure, an electron density feature is observed within the central vestibule, which could represent a trapped MK801 molecule. The central vestibule and the mutants (located in the selectivity filter) are in very close proximity (Lee et al., 2014) . Therefore, it may be that these mutants Table 1 for IC 50 values and statistical significance). Data represent mean ± SEM from 2 to 8 dose-response curves (see Table 1 ).
influence the integrity of the channel blocker site. Consequently, as memantine is also considered to bind in the central vestibule, patients with a Val618Gly substitution might not respond to memantine, a clinically used non-selective NMDA receptor inhibitor (Bachurin et al., 2001 ), while they may be able to respond to radiprodil. The differential effects of memantine on N615I and V618G variants were unexpected considering that both variants abolish Mg 2þ block. Previous mutagenesis studies showed that in N615Q variants, memantine's inhibitory effect was decreased 9 times (Kashiwagi et al., 2002) , suggesting that an asparagine substitution by glutamine decreases memantine binding while asparagine substitution by isoleucine does not. This also suggests that memantine might be efficacious in patients with the N615I mutation, especially since this compound also displays anticonvulsive and neuroprotective effect in preclinical models (Parsons et al., 1999; Wenk et al., 2006) .
Therapeutic use of radiprodil in epilepsy
It may be hypothesized that selective GluN2B inhibitors could also be efficacious in epilepsies caused by GRIN1 gain of function mutations, by blocking heteromers containing GluN1 and GluN2B subunits. Currently it is not known what are the direct consequences of the GRIN2B mutations on seizure susceptibility, therefore further physiological characterization of epilepsy-associated mutations in cell cultures and animal models will help determine their impact on seizure initiation and/or on epileptogenesis. However, it is very likely that the gain of function mutation described here, and in previous studies, contribute to neuronal excitability in subjects carrying such mutations which have been linked with epileptic encephalopathies.
We also demonstrated that radiprodil maintained its potency in high glycine concentrations, indicating it might be a useful treatment option for other epileptic disorders not limited to GRIN2B gain of function mutations. For example, in nonketotic hyperglycinemia, that leads to severe neonatal myoclonic encephalopathy, the typical treatment paradigm includes sodium benzoate, to reduce plasma and CSF glycine levels, and non-selective NMDA receptor antagonists (dextromethorphan or ketamine), to block the excitatory effects of glycine at the NMDA receptor site (Mulligan, 2013) . Selective inhibition of GluN2B could be considered as a potential alternative treatment option for this and other infantile epileptic encephalopathies also due the predominant expression of GluN2B-containing NMDA receptors during this early developmental period (Rakhade and Jensen, 2009 ) and corresponding agedependent anticonvulsant effects of GluN2B selective compounds (Mares and Mikulecka, 2009; Mares, 2014; Szczurowska and Mares, 2015) . Acidification of the brain is a mechanism observed during prolonged seizures and during ischemia Siesjo et al., 1985 , Xiong et al., 2000 . Here, we demonstrate that radiprodil's potency is higher at pH 7.0 than at pH 7.6, suggesting that radiprodil may retain its ability to block glutamate-induced NMDA currents even under acidic conditions that manifest under long term seizures. These results are in line with other studies, reporting increased potency of other selective GluN2B antagonists at acidic pH (Pahk and Williams, 1997; Yuan et al., 2015) .
Conclusions
Our results indicate that selective targeting of GluN2B-containing NMDA receptors may yield better therapeutic results than non-selective NMDA receptor inhibition in epileptic encephalopathies caused by NMDA gain of function. Among the distinct classes of NMDA receptor inhibitors, high-affinity competitive and non-competitive NMDA receptor antagonists proved unsuitable for human use due to prominent adverse effects, including psychotomimetic actions (Low and Roland, 2004; Alaghband-Rad et al., 2013) . The identification of de novo mutations in the GRIN2B gene in epileptic encephalopathies has led to new potential therapeutic strategies based on precision medicine with NMDA receptor inhibitors (Pierson et al., 2014; Marwick et al., 2015; Li et al., 2016) . Our study clearly illustrates that functional understanding of NMDA receptor variants together with in-depth in vitro pharmacological characterization are going to be critical for proper selection of future therapeutic agents. 
